Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurotech International ( (AU:NTI) ) has issued an update.
Neurotech International has issued new ordinary fully paid shares without a prospectus under the Corporations Act, confirming that it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information that would reasonably be expected in a formal disclosure document. The board-authorised move signals routine capital management by the clinical-stage paediatric neurology specialist, with the company emphasising regulatory compliance as it advances development of its NTI164 cannabinoid therapy across multiple neurological indications.
More about Neurotech International
Neurotech International is a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, developing its broad-spectrum oral cannabinoid drug candidate NTI164. The company has reported statistically significant and clinically meaningful results from Phase I/II and Phase II/III trials in Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome, and has ethics clearance to commence a Phase I/II clinical trial in spastic cerebral palsy.
Average Trading Volume: 1,253,685
Technical Sentiment Signal: Sell
Current Market Cap: A$17.84M
For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.